News

Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...
An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...
Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...
Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...